6-[(2R,4R,5S,6S)-4,5-dihydroxy-6-methyloxan-2-yl]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
Internal ID | 0d29d901-7916-4c6b-8563-e028f6a46786 |
Taxonomy | Phenylpropanoids and polyketides > Flavonoids > Flavonoid glycosides > Flavonoid O-glycosides > Flavonoid-7-O-glycosides |
IUPAC Name | 6-[(2R,4R,5S,6S)-4,5-dihydroxy-6-methyloxan-2-yl]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one |
SMILES (Canonical) | CC1C(C(CC(O1)C2=C(C=C3C(=C2O)C(=O)C=C(O3)C4=CC(=C(C=C4)OC)O)OC5C(C(C(C(O5)CO)O)O)O)O)O |
SMILES (Isomeric) | C[C@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C=C3C(=C2O)C(=O)C=C(O3)C4=CC(=C(C=C4)OC)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O |
InChI | InChI=1S/C28H32O14/c1-10-23(33)14(32)7-17(39-10)22-19(41-28-27(37)26(36)24(34)20(9-29)42-28)8-18-21(25(22)35)13(31)6-16(40-18)11-3-4-15(38-2)12(30)5-11/h3-6,8,10,14,17,20,23-24,26-30,32-37H,7,9H2,1-2H3/t10-,14+,17+,20+,23+,24+,26-,27+,28+/m0/s1 |
InChI Key | VIFHMFGCECKEBO-VHCRMOMMSA-N |
Popularity | 1 reference in papers |
Molecular Formula | C28H32O14 |
Molecular Weight | 592.50 g/mol |
Exact Mass | 592.17920569 g/mol |
Topological Polar Surface Area (TPSA) | 225.00 Ų |
XlogP | -0.20 |
Atomic LogP (AlogP) | -0.37 |
H-Bond Acceptor | 14 |
H-Bond Donor | 8 |
Rotatable Bonds | 6 |
There are no found synonyms. |
Target | Value | Probability (raw) | Probability (%) |
---|---|---|---|
Human Intestinal Absorption | - | 0.4600 | 46.00% |
Caco-2 | - | 0.8930 | 89.30% |
Blood Brain Barrier | - | 0.7250 | 72.50% |
Human oral bioavailability | - | 0.7286 | 72.86% |
Subcellular localzation | Mitochondria | 0.5432 | 54.32% |
OATP2B1 inhibitior | - | 0.7138 | 71.38% |
OATP1B1 inhibitior | + | 0.8687 | 86.87% |
OATP1B3 inhibitior | + | 0.9467 | 94.67% |
MATE1 inhibitior | - | 0.9800 | 98.00% |
OCT2 inhibitior | - | 0.8750 | 87.50% |
BSEP inhibitior | + | 0.7267 | 72.67% |
P-glycoprotein inhibitior | - | 0.6096 | 60.96% |
P-glycoprotein substrate | + | 0.6771 | 67.71% |
CYP3A4 substrate | + | 0.6468 | 64.68% |
CYP2C9 substrate | - | 0.8387 | 83.87% |
CYP2D6 substrate | - | 0.8456 | 84.56% |
CYP3A4 inhibition | - | 0.8654 | 86.54% |
CYP2C9 inhibition | - | 0.9397 | 93.97% |
CYP2C19 inhibition | - | 0.9602 | 96.02% |
CYP2D6 inhibition | - | 0.9425 | 94.25% |
CYP1A2 inhibition | - | 0.9003 | 90.03% |
CYP2C8 inhibition | + | 0.7034 | 70.34% |
CYP inhibitory promiscuity | - | 0.8353 | 83.53% |
UGT catelyzed | + | 0.6000 | 60.00% |
Carcinogenicity (binary) | - | 1.0000 | 100.00% |
Carcinogenicity (trinary) | Non-required | 0.7120 | 71.20% |
Eye corrosion | - | 0.9914 | 99.14% |
Eye irritation | - | 0.9213 | 92.13% |
Skin irritation | - | 0.8198 | 81.98% |
Skin corrosion | - | 0.9569 | 95.69% |
Ames mutagenesis | + | 0.5635 | 56.35% |
Human Ether-a-go-go-Related Gene inhibition | + | 0.7534 | 75.34% |
Micronuclear | + | 0.6100 | 61.00% |
Hepatotoxicity | - | 0.8500 | 85.00% |
skin sensitisation | - | 0.9237 | 92.37% |
Respiratory toxicity | + | 0.6111 | 61.11% |
Reproductive toxicity | + | 0.8556 | 85.56% |
Mitochondrial toxicity | + | 0.5625 | 56.25% |
Nephrotoxicity | - | 0.9636 | 96.36% |
Acute Oral Toxicity (c) | III | 0.6944 | 69.44% |
Estrogen receptor binding | + | 0.8162 | 81.62% |
Androgen receptor binding | + | 0.6428 | 64.28% |
Thyroid receptor binding | - | 0.5000 | 50.00% |
Glucocorticoid receptor binding | + | 0.5486 | 54.86% |
Aromatase binding | - | 0.5000 | 50.00% |
PPAR gamma | + | 0.6982 | 69.82% |
Honey bee toxicity | - | 0.7152 | 71.52% |
Biodegradation | - | 0.7750 | 77.50% |
Crustacea aquatic toxicity | - | 0.6949 | 69.49% |
Fish aquatic toxicity | + | 0.6921 | 69.21% |
Proven Targets:
CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
---|---|---|---|---|---|
No proven targets yet! |
Predicted Targets (via Super-PRED):
CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
---|---|---|---|---|
CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.48% | 91.11% |
CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 99.01% | 85.14% |
CHEMBL1951 | P21397 | Monoamine oxidase A | 97.78% | 91.49% |
CHEMBL2635 | P51452 | Dual specificity protein phosphatase 3 | 97.73% | 94.00% |
CHEMBL2581 | P07339 | Cathepsin D | 97.40% | 98.95% |
CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 96.29% | 89.00% |
CHEMBL3880 | P07900 | Heat shock protein HSP 90-alpha | 94.78% | 96.21% |
CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 93.65% | 96.09% |
CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 93.10% | 86.33% |
CHEMBL3137262 | O60341 | LSD1/CoREST complex | 92.65% | 97.09% |
CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 89.06% | 90.71% |
CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 87.34% | 95.89% |
CHEMBL220 | P22303 | Acetylcholinesterase | 87.29% | 94.45% |
CHEMBL241 | Q14432 | Phosphodiesterase 3A | 87.11% | 92.94% |
CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 86.92% | 95.56% |
CHEMBL4016 | P42262 | Glutamate receptor ionotropic, AMPA 2 | 86.50% | 86.92% |
CHEMBL3091268 | Q92753 | Nuclear receptor ROR-beta | 84.89% | 95.50% |
CHEMBL5339 | Q5NUL3 | G-protein coupled receptor 120 | 84.80% | 95.78% |
CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 81.24% | 96.00% |
CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 81.22% | 99.17% |
CHEMBL1860 | P10827 | Thyroid hormone receptor alpha | 81.08% | 99.15% |
CHEMBL3713062 | P10646 | Tissue factor pathway inhibitor | 80.18% | 97.33% |
PubChem | 11039229 |
NPASS | NPC208668 |
LOTUS | LTS0188009 |
wikiData | Q105286817 |